S1203
Clinical - Urology
ESTRO 2026
age groups. Baseline scores and score changes at 6mFU of the SA domain were higher in younger patients. It may allow anticipation with a personalized medical approach and enhanced information. Keywords: Prostate cancer, triptorelin, quality of life Digital Poster 1920 Not too soft, not too hard: 3-year outcomes of an intermediate hypofractionation regimen for localized prostate cancer. Gerard Meca 1 , Joel Mases 1 , Elías Gomis 1 , Carlos Clavell 1 , Sara Moreno 1 , Tanny Daniela Barreto 1 , Solanche Jasmin Santillán 1 , Ana Gabriela Córdova 1 , Rebeca Bagó 1 , Luisa Delgado 1 , Izaskun Valduvieco 1 , Paula Navarro-Palomas 1 , Artur Latorre-Musoll 1 , Elisabeth Escudero 1 , Cristina Castro 1 , María Dolores Molina 1 , Josep Carreras 1 , Ignacio Asiain 2 , Agustín Franco 2 , María José Ribal 2 , Sandra Jorcano 3 , Meritxell Mollà 1 1 Radiation Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. 2 Urology, Hospital Clínic de Barcelona, Barcelona, Spain. 3 Radiation Oncology, Centro Médico Teknon, Barcelona, Spain Purpose/Objective: Moderate hypofractionation is the standard for localized prostate cancer. However, the intermediate range between moderate ( ≈ 3 Gy/fraction) and extreme hypofractionation ( ≥ 5 Gy/fraction) remains underexplored. We report clinical outcomes and toxicity from a large single-institution series treated with 56 Gy in 14 alternate-day fractions (4 Gy/fraction), a schedule bridging this gap [1]. Material/Methods: We retrospectively analysed 180 consecutive patients enrolled in a prospective cohort approved by the Ethics Committee (HCB/2019/0513), treated between July 2019 and September 2023. All received image- guided VMAT to 56 Gy in 14 alternate-day fractions over 5 weeks, targeting the prostate with/without seminal vesicles. Polymer-based fiducial markers were implanted in all but one patient for image guidance. Androgen-deprivation therapy (ADT) was prescribed according to risk group. Toxicities were graded using CTCAE v5.0. Biochemical progression-free survival (bPFS) and overall survival (OS) were estimated by Kaplan–Meier method, and dose–toxicity associations were evaluated using Mann–Whitney U, logistic regression, ROC, and χ² tests. Results: After a median follow-up of 37.5 months (mean 39.1; range 1.4–71.6), 3-year bPFS and OS were 94.9 % (Figure 1) and 99.4 %, respectively. Baseline characteristics and toxicity profiles are summarized in Table 1. Acute gastrointestinal (GI) toxicity was mild,
Conclusion: This pooled analysis of a high number of patients provided several data in the real-life setting. Deteriorations of HRQoL subscales (HTRS and SA) were aligned with ADT literature. In this large population, baseline description by age groups showed clinical and therapeutical differences between
Made with FlippingBook - Share PDF online